Allegations include medically unnecessary skin substitute use and “phantom” graft procedures
WASHINGTON, DC, August 26, 2026 — Federal prosecutors have accused Sarasota advanced practice registered nurse Leigh Tesar of causing more than $118 million in false Medicare claims through a wound-care operation that allegedly combined unnecessary skin substitutes, fabricated clinical documentation, patient-referral kickbacks, and procedures that never occurred.
The June 17, 2026, indictment in the Middle District of Florida charges Tesar alongside registered nurses Walter Presha Jr. and Koby Evans, while identifying Tesar as the defendant responsible for five substantive health care fraud counts involving specific beneficiaries and disputed allograft claims.
Medicare allegedly paid Tesar and Tesar Primecare more than $61 million over an eighteen-month period from approximately May 2024 through November 2025, while federal investigators separately seized about $11.8 million from financial accounts connected to the pending case.
The Justice Department’s official Middle District of Florida announcement describes products allegedly applied to infected wounds, used on terminally ill beneficiaries whose wounds could not heal, or billed as completed applications when no corresponding procedure was performed.
Every assertion about fraudulent billing, unnecessary treatment, falsified records, illegal inducements, kickbacks, concealment, and personal spending remains an allegation, because an indictment establishes charges for litigation but does not determine guilt under the reasonable-doubt standard governing a criminal trial.
The indictment’s two kinds of alleged false billing
The prosecution presents two conceptually different categories of disputed wound-care claims: one involving products or applications that allegedly occurred but lacked medical necessity, and another involving allografts or application services that prosecutors say were never furnished as represented.
That distinction matters because a medical-necessity dispute can require expert evaluation of wound condition, treatment history, clinical judgment, coverage policy, infection, and healing potential, whereas a never-performed procedure can turn upon whether any product was actually opened, placed, documented, or delivered.
The word “phantom” does not appear as a separately charged federal offense in the indictment, but it concisely describes the government’s accusation that Medicare received claims for purported allograft applications that beneficiaries never received.
Prosecutors will still need to prove knowing and willful fraud rather than a billing mistake, documentation lapse, product-return problem, coding disagreement, or administrative mismatch, and the evidentiary path for each challenged claim may differ according to its underlying factual theory.
Evidence of an allegedly nonexistent application could include wound photographs, signed delivery records, product lot numbers, inventory logs, visit notes, electronic chart timestamps, patient testimony, discarded packaging, distributor invoices, and the claim transmitted to Medicare after the supposed treatment date.
When those sources align, they can reconstruct a clinical encounter with unusual precision, but when records conflict or remain incomplete, prosecutors and defense lawyers may disagree sharply about whether an absent document proves non-performance or merely exposes imperfect recordkeeping.
The indictment also alleges that some products were not provided “as represented,” a broader formulation that could encompass discrepancies in product identity, quantity, wound dimensions, provider participation, application details, or supporting documentation beyond the stark allegation that no graft procedure happened.
By combining alleged phantom procedures with medically unnecessary treatment, the government can present a layered theory in which some claims supposedly failed because nothing occurred, while others allegedly failed because something occurred that Medicare should never have financed.
Why wound allografts can generate extraordinary claims
The products at the center of the case are wound allografts, frequently described within reimbursement discussions as skin substitutes, including materials derived from donated human placental tissue and designed to support healing when ordinary wound management has not produced adequate improvement.
These products may serve legitimate clinical purposes for appropriately selected patients, yet their reimbursable value can become exceptionally large when pricing is calculated by square centimeter and multiplied across substantial wound areas, repeat applications, and multiple treatment visits.
The resulting economics mean a measurement entered into a chart can influence not only clinical planning but also the number of product units on a claim, making accurate wound dimensions, wastage reporting, and contemporaneous documentation essential safeguards against inflated billing.
Medicare Part B generally pays qualified practitioners and suppliers for covered, reasonable, and necessary items and services, but reimbursement depends upon truthful coding, reliable records, actual performance, applicable coverage criteria, and freedom from referral arrangements prohibited by federal law.
The indictment identifies First Coast Service Options as the Medicare administrative contractor responsible for processing relevant Florida claims, and it describes coverage expectations governing when continued wound treatment and skin-substitute applications could qualify for federal reimbursement.
For diabetic foot ulcers and venous leg ulcers, the cited framework generally contemplated a documented course of conservative treatment before advanced products, together with attention to infection control, pressure, drainage, debridement, underlying disease, and measurable evidence that a wound retained healing potential.
Prosecutors allege Tesar applied allografts without attempting or confirming adequate conservative care, continued using them when wounds were not responding, treated infected wounds, and selected products solely to maximize profit instead of matching material choice to individualized clinical need.
Those allegations place patient-specific medicine at the heart of the case, because a jury may eventually hear competing explanations about what each wound looked like, what therapies preceded an application, what alternatives existed, and what outcome a practitioner could reasonably anticipate.
Terminal illness, infection, and realistic healing potential
Among the most consequential allegations is the government’s claim that allografts were placed on wounds that could not heal because the patients were terminally ill, transforming a reimbursement dispute into a broader question about clinical purpose, vulnerability, and treatment burden near life’s end.
Terminal illness alone does not establish that every wound intervention is inappropriate, since palliative care may still include measures addressing pain, odor, infection, drainage, bleeding, comfort, or dignity even when complete closure is no longer a realistic objective.
The prosecution’s theory instead appears to focus upon whether repeated high-cost allograft applications were represented as restorative treatment despite medical circumstances making healing unattainable, and whether Medicare coverage requirements were knowingly bypassed to obtain payment from a federal program.
Infected wounds present another evidentiary fault line because infection may require stabilization and targeted management before certain advanced products become appropriate, while the indictment alleges applications proceeded despite conditions that rendered the claimed treatment medically unreasonable and unnecessary.
Defense experts could dispute the government’s retrospective interpretation, distinguish localized colonization from active infection, explain clinical decisions based on the information available at the time, or argue that individual beneficiaries retained sufficient healing potential despite serious underlying disease.
Prosecution experts, by contrast, may compare records with coverage criteria and accepted wound-care practice, emphasizing photographs, laboratory findings, treatment response, comorbidities, prognosis, application frequency, and the absence of documented conservative measures preceding expensive interventions.
The legal question will not be answered by the emotional force of words such as terminal, infected, or phantom alone, because criminal liability requires admissible evidence linking disputed care to knowingly false claims and the charged defendant’s specific intent.
Medical records as the bridge between care and payment
Clinical documentation provides the narrative through which Medicare evaluates a claim, recording wound size, depth, location, duration, infection status, prior treatment, product selection, units used, units discarded, response over time, and the practitioner’s medical-necessity assessment.
Prosecutors accuse Tesar and others of falsifying those records to create an appearance of compliance, including by documenting treatments that allegedly never occurred, inventing earlier wound documentation, misreporting patient conditions, and claiming conservative care was personally provided when it was not.
If proven, such fabrication could help the government move beyond showing that a claim was incorrect, because deliberately manufactured clinical history may support an inference that participants understood the coverage problem and attempted to construct a reimbursement-ready explanation after the fact.
The defense can nevertheless challenge whether a questioned entry was intentionally false, copied forward through ordinary electronic-record functions, entered by another worker, based upon information supplied by a patient or caregiver, or simply misunderstood when investigators reconstructed the file months later.
Electronic metadata may therefore become especially important, revealing who created or modified particular notes, whether templates were reused, when photographs were uploaded, whether signatures were added after billing, and how documentation timing corresponded with product orders and claim submissions.
Patient and caregiver testimony could provide another important check, although memory may be imperfect when witnesses were seriously ill, received numerous home visits, encountered several providers, or were asked long afterward to distinguish one advanced wound product from another.
Product-level evidence could either reinforce or complicate those recollections by showing shipment dates, quantities, serial or lot identifiers, storage locations, returns, wastage, and whether available inventory could physically support the volume of applications represented across beneficiary records.
Five charged claims provide concrete trial anchors
Counts one through five identify five Medicare beneficiaries by initials and list specific service dates, submission dates, billed amounts, and payments, giving prosecutors defined transactions through which they must prove Tesar knowingly executed or attempted to execute the alleged health care fraud scheme.
Together, those five executions involved approximately $3.96 million billed and $2.82 million paid, with service dates ranging from October 2024 through August 2025 and claim submissions occurring from November 2024 through August 2025.
The smallest charged transaction allegedly sought approximately $288,350 and produced approximately $199,769 in payment, while the largest allegedly sought approximately $1.11 million and produced approximately $854,311, demonstrating the exceptional value attached to individual treatment episodes.
The remaining three charged claims allegedly sought approximately $1.06 million, $871,200, and $630,475, producing respective Medicare payments of approximately $727,168, $599,583, and $443,043, according to the amounts stated in the federal charging document.
Those five claims are not interchangeable with the indictment’s broader $118 million allegation, because charged executions provide transaction-specific counts, whereas the larger figure describes the government’s asserted scheme-wide universe of false and fraudulent submissions throughout the eighteen-month period.
At trial, prosecutors may use the five beneficiaries as detailed case studies before connecting them to larger billing patterns, while defense counsel can insist that each patient, record, product, and representation receive separate consideration rather than being overwhelmed by the aggregate number.
Referral payments and product pricing surround the claims
The medical-necessity and phantom-procedure allegations sit inside a wider kickback case, with prosecutors accusing Presha and Evans of locating Medicare beneficiaries with wounds and referring them to Tesar through purported sales arrangements maintained by an unnamed Pennsylvania allograft company.
Presha allegedly owned Universal Nursing and Wellness and used the fictitious name W.P. Enterprises, while Evans allegedly owned Healing His Way, and the indictment identifies accounts associated with those businesses as destinations for disputed distributor payments.
According to prosecutors, the sales agreements were shams because compensation rewarded beneficiary referrals rather than legitimate independent marketing, allowing Tesar to obtain patients, purchase products from the distributor, submit high-value claims, and route referral payments through related commercial accounts.
The indictment cites communications in which Tesar allegedly calculated a twenty-percent share from approximately $4.07 million in invoices, discussed higher compensation associated with a product costing $2,000 per square centimeter, and proposed switching patients toward the more expensive material.
Those communications could support the government’s claim that product price and referral revenue influenced treatment decisions, although defendants may argue that prosecutors stripped commercial discussions from their context or mischaracterized lawful compensation for services actually performed.
On August 15, 2025, the distributor allegedly deposited approximately $397,570 into the W.P. Enterprises account and approximately $10,998 into the Healing His Way account, creating the two transactions underlying the separate payment and receipt kickback counts.
The government further alleges beneficiaries were encouraged to begin or continue treatment through misrepresented costs, unlawfully waived copayments, free medical supplies, jewelry, and a leather recliner, adding patient inducements to the alleged financial incentives affecting recruiters and providers.
These accusations matter to the billing counts because claims resulting from illegal kickbacks can be ineligible for federal reimbursement even when an item was physically delivered, giving prosecutors another theory distinct from both nonexistent performance and disputed medical necessity.
Audit scrutiny and the alleged ownership change
The indictment alleges that after Medicare initiated an audit, Tesar removed her name as Primecare’s owner from Florida corporate records while continuing to maintain ownership and managerial control, purportedly seeking to avoid scrutiny of continued claim submissions.
Corporate records alone may not establish actual control, so investigators are likely to examine banking authority, payroll decisions, provider enrollment information, contracts, electronic communications, employee instructions, profit distributions, and access to the systems through which Primecare operated and billed.
The timing of any ownership change could become circumstantial evidence of consciousness of wrongdoing, but the defense may offer legitimate business, licensing, tax, administrative, or personal explanations and challenge whether the change concealed anything material from Medicare.
Because an audit ordinarily compares claim documentation with coverage requirements, the parties may also dispute what Medicare requested, what Primecare produced, whether omissions were intentional, and how participants responded after learning that particular records or billing patterns were under review.
The alleged continuation of billing after audit scrutiny could strengthen the prosecution’s intent theory if supported by reliable evidence, while an effective defense could show corrective action, good-faith reliance upon advisers, or uncertainty regarding rules governing complex wound-product reimbursement.
Payments, seizures, and contested proceeds
The indictment says Medicare paid Tesar and Primecare more than $61 million on the broader claim universe, but that figure remains an alleged proceeds or loss measure rather than a judicial finding that every associated dollar resulted from criminal conduct.
Federal authorities also report seizing approximately $11.8 million from accounts associated with Tesar, including funds held at Bank of America, Fidelity Investments, and Cogent Bank, while seeking forfeiture tied to proceeds allegedly traceable to charged offenses.
Prosecutors allege scheme proceeds financed more than $215,000 in Tampa Bay Buccaneers tickets and a luxury suite at Raymond James Stadium, together with more than $400,000 in fine art purchased during the period described by investigators.
Expensive purchases can create a vivid courtroom narrative, yet their legal significance depends upon admissibility and tracing because conspicuous consumption does not independently prove that medical care was unnecessary, a procedure was fictional, or reimbursement money constituted criminal proceeds.
The forfeiture allegations identify approximately $61.63 million attributed to Tesar, approximately $3.19 million attributed to Presha, and approximately $263,223 attributed to Evans, while permitting substitute-property claims if directly traceable assets cannot be located or recovered.
Seizure does not equal final forfeiture, and defendants or qualifying third parties may contest ownership, traceability, commingling, statutory authority, valuation, substitute-property treatment, and the relationship between particular assets and any offense ultimately proven in court.
Ten counts, three defendants, and an unresolved prosecution
The indictment includes ten counts: five health care fraud counts against Tesar, one conspiracy count against all three defendants, two kickback-payment counts against Tesar, and one kickback-receipt count against each of Presha and Evans.
Regional reporting by WWSB identified Tesar as a Sarasota nurse practitioner and summarized the allegations against Presha and Evans, while emphasizing that the charging document describes accusations rather than established findings of guilt.
Each defendant’s criminal responsibility must be evaluated separately, meaning evidence that may be admissible against one person does not automatically prove another person’s knowledge, participation, intent, or liability merely because their professional activities intersected within the same alleged network.
Health care fraud under the charged statute requires proof involving a knowing and willful scheme directed at a health care benefit program, while the kickback charges carry their own requirements concerning remuneration, referrals, federal-program business, and culpable intent.
The conspiracy count gives prosecutors a framework for connecting alleged referrals, billing, product selection, payments, communications, and concealment, but the government must still prove an unlawful agreement and each defendant’s legally required participation rather than relying on association.
Grand jury proceedings do not include the full adversarial testing available at trial, so the indictment’s allegations have not yet undergone public cross-examination, competing expert review, defense evidence, final evidentiary rulings, or deliberation by a trial jury.
A signature case from the 2026 national takedown
Federal authorities announced the Tesar prosecution during the 2026 National Health Care Fraud Takedown, which charged 455 defendants, including 90 physicians and other licensed professionals, across 56 judicial districts and 45 states and territories.
The broader initiative targeted alleged schemes involving more than $6.5 billion in false claims, while authorities reported seizing over $182 million in cash, real estate, vehicles, jewelry, and other property through the nationwide collection of investigations.
Claims analytics can identify providers whose allograft spending, square-centimeter utilization, patient concentration, application frequency, product mix, or payment totals differ dramatically from peers, allowing investigators to move from statistical anomalies toward individual records and financial relationships.
An outlier does not establish fraud by itself, but unusually concentrated billing can direct attention toward whether patient files support submitted units, whether photographs document treatment progression, whether referral sources received compensation, and whether actual inventory matches claimed use.
The Tesar case therefore illustrates how a data-intensive inquiry can become a deeply human prosecution, moving from millions of standardized billing entries into the treatment histories of vulnerable beneficiaries whose wounds, prognoses, choices, and memories may eventually be examined in court.
Publicity arrives before adjudication
Major health care fraud allegations can affect professional licensing, Medicare participation, banking relationships, employees, referral partners, patients, and search results long before a judge or jury resolves the evidence, creating reputational consequences that do not track the measured pace of litigation.
Organizations facing comparable scrutiny may need disciplined crisis public relations management that coordinates verified public statements with legal counsel, preserves documents, corrects demonstrable inaccuracies, respects court restrictions, and avoids declaring either guilt or exoneration before the evidentiary record develops.
Over time, lawful reputation rebuilding strategies can present accurate procedural developments, documented reforms, verified credentials, and meaningful accountability, without attempting to erase legitimate journalism, manipulate public records, intimidate critics, or conceal information relevant to patients and regulators.
Nothing in the public materials reviewed indicates that Amicus International Consulting represents Tesar, Presha, Evans, Primecare, or any connected company, and these observations address only general communication challenges arising when unresolved federal allegations become permanently searchable.
Responsible reporting should therefore preserve attribution, distinguish the indictment’s accusations from proven facts, avoid treating the $118 million headline as an adjudicated loss, and update coverage if later motions, pleas, dismissals, acquittals, convictions, sentences, or forfeiture rulings change the record.
What the evidence will have to establish
Prosecutors seeking convictions will likely connect Medicare claim data with clinical records, product orders, photographs, communications, bank transfers, corporate filings, witness testimony, and expert analysis explaining why specified applications were unnecessary, ineligible, misrepresented, or entirely unperformed.
Defense lawyers can separate each theory, insisting that questionable medical necessity does not prove phantom treatment, that imperfect documentation does not establish willful fraud, and that commercial payments do not become criminal kickbacks without the required referral bargain and intent.
Jurors may ultimately be asked to determine whether particular allografts reached particular wounds, whether claimed quantities matched actual use, whether beneficiaries could reasonably heal, whether records truthfully described prior care, and whether reimbursement decisions were deliberately manipulated.
They may also need to decide whether the broader financial arrangement rewarded lawful sales work or purchased Medicare referrals, whether product choices reflected medicine or margin, and whether actions following the audit demonstrated concealment, confusion, correction, or ordinary corporate administration.
Until evidence and due process resolve those questions, the APRN Leigh Tesar wound-care billing fraud case remains a pending federal prosecution, and Tesar, Presha, and Evans retain the presumption of innocence guaranteed to every criminal defendant.
